Baseline characteristics and clinical outcome of patients who received allo-HCT transplantation after blinatumomab (N = 85)
| . | Value . |
|---|---|
| Age, median (range), y | 59 (18-72) |
| Median number or prior therapies (range) | 2 (2-6) |
| Prior allo-HCT | 5 (6) |
| Time from remission to allo-HCT, median (range), mo | 1.7 (0.2-13.2) |
| Type of allo-HCT | |
| Matched related donor | 31 (37) |
| Matched unrelated donor | 36 (42) |
| Haploidentical | 13 (15) |
| Cord blood | 5 (6) |
| Complication after allo-HCT | |
| aGVHD | 28 (33) |
| cGVHD | 14 (16.5) |
| Veno-occlusive disease | 2 (2) |
| Infectious complication | 12 (14) |
| Transplant-related mortality in 100 d | 6 (7) |
| Progression-free survival | NR (66% progression free at 2 y) |
| Overall survival | NR (62% alive at 2 y) |
| . | Value . |
|---|---|
| Age, median (range), y | 59 (18-72) |
| Median number or prior therapies (range) | 2 (2-6) |
| Prior allo-HCT | 5 (6) |
| Time from remission to allo-HCT, median (range), mo | 1.7 (0.2-13.2) |
| Type of allo-HCT | |
| Matched related donor | 31 (37) |
| Matched unrelated donor | 36 (42) |
| Haploidentical | 13 (15) |
| Cord blood | 5 (6) |
| Complication after allo-HCT | |
| aGVHD | 28 (33) |
| cGVHD | 14 (16.5) |
| Veno-occlusive disease | 2 (2) |
| Infectious complication | 12 (14) |
| Transplant-related mortality in 100 d | 6 (7) |
| Progression-free survival | NR (66% progression free at 2 y) |
| Overall survival | NR (62% alive at 2 y) |
Values are n (%) unless otherwise noted.